Susan Margaret Sundström
Corporate Officer/Principal bij The University of Southampton
Profiel
Susan Margaret Sundström is currently a Principal at The University of Southampton.
Previously, she was a Non-Executive Director at Synairgen Plc from 2003 to 2009, and a Non-Executive Director at Karus Therapeutics Ltd.
She also held a position as a Principal at AstraZeneca PLC.
Actieve functies van Susan Margaret Sundström
Bedrijven | Functie | Begin |
---|---|---|
The University of Southampton | Corporate Officer/Principal | - |
Eerdere bekende functies van Susan Margaret Sundström
Bedrijven | Functie | Einde |
---|---|---|
SYNAIRGEN PLC | Directeur/Bestuurslid | 03-09-2009 |
ASTRAZENECA PLC | Corporate Officer/Principal | - |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ASTRAZENECA PLC | Health Technology |
SYNAIRGEN PLC | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |